{
  "meta": {
    "title": "60_Pharmacology_Neet_2024",
    "url": "https://brainandscalpel.vercel.app/60-pharmacology-neet-2024-2590fb81.html",
    "scrapedAt": "2025-11-30T12:58:12.259Z"
  },
  "questions": [
    {
      "text": "A man presents with mixed infection of Plasmodium vivax and Plasmodium falciparum in a health centre in Rajasthan. What is the dosage of the treatment given on the second day?",
      "choices": [
        {
          "id": 1,
          "text": "4 tablets of Artesunate 50mg + 6 tablets of Primaquine 2.5mg"
        },
        {
          "id": 2,
          "text": "4 tablets of Artesunate 50mg + 6 tablets of Primaquine 7.5mg"
        },
        {
          "id": 3,
          "text": "4 tablets of Artesunate 50mg + Sulphadoxine 1500mg + 6 tablets of Primaquine 2.5mg"
        },
        {
          "id": 4,
          "text": "4 tablets of Artesunate 45mg + Sulphadoxine 1500mg  + 6 tablets of Primaquine 7.5mg"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The dosage of the treatment given on the <strong>second day</strong> for <strong>mixed infection</strong> with <em><strong>Plasmodium vivax </strong></em>and<em><strong> Plasmodium falciparum </strong></em>is <strong>4 tablets of Artesunate 50mg + 6 tablets of Primaquine 2.5mg.</strong></p>\n<p>For treating mixed infections of <strong><em>Plasmodium vivax</em></strong> and <em><strong>Plasmodium falciparum</strong></em>, the following treatment regimen is recommended. This approach ensures comprehensive treatment by addressing both the <strong>blood stages</strong> of <strong><em>Plasmodium falciparum</em> </strong>with <strong>ACT</strong> and the <strong>liver stages</strong> of <strong><em>Plasmodium vivax</em></strong> with <strong>Primaquine</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a1052845f6b14466b77a39d656743628x1280x1194.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Treatment of Malaria</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p><strong> Drug of Choice</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Primaquine Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. vivax malaria </strong></p>\n</td>\n<td>\n<p><strong>Chloroquine</strong> 25 mg/kg divided as:</p>\n<p>10mg/kg on day 1</p>\n<p>10mg/kg on day 2</p>\n<p>5mg/kg on day 3</p>\n</td>\n<td>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. falciparum malaria</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days&nbsp;</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.75mg/kg on day 2</p>\n<p>0.75mg/kg on day 2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mixed infection</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.25 mg/kg for 14 days</p>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Resistance to ACT/ Severe malaria </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Quinine </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong> -</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. vivax</strong></p>\n</td>\n<td>\n<p><strong>Chloroquine </strong></p>\n</td>\n<td>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. falciparum</strong></p>\n</td>\n<td>\n<p>1<sup>st&nbsp;</sup>trimester: <strong>Quinine</strong></p>\n<p>2<sup>nd</sup> and 3<sup>rd</sup> trimester<strong>: Area specific ACT</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>ACT:&nbsp;</strong>artemisinin-based combination therapy</p>\n<p><strong>AL:</strong>&nbsp;artemether-lumefantrine</p>\n<p><strong>SP</strong>: Sulfadoxine-<wbr />Pyrimethamine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6721",
      "difficulty": "hard"
    },
    {
      "text": "Which drug is used to treat multiple myeloma that is known to cause reactivation of Herpes Zoster?",
      "choices": [
        {
          "id": 1,
          "text": "Bortezomib "
        },
        {
          "id": 2,
          "text": "Lenalidomide "
        },
        {
          "id": 3,
          "text": "Daratumumab "
        },
        {
          "id": 4,
          "text": "Elotuzumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The drug used to treat <strong>multiple myeloma </strong>and that has the potential to cause<strong> reactivation</strong> of <strong>Herpes Zoster</strong> is <strong>bortezomib</strong>.</p>\n<p>Bortezomib is an <strong>inhibitor </strong>of <strong>proteasome-mediated protein degradation</strong>. It is central to the treatment of <strong>multiple myeloma</strong>, both untreated and relapsed. Bortezomib is given <strong>intravenously or subcutaneously</strong> and dosage depends upon the disease, route of administration, and the patient’s history.  It is known to predispose patients to the <strong>reactivation</strong> of<strong> herpesvirus</strong>, including <strong>Herpes Zoster</strong>.</p>\n<p>Adverse effects include <strong>thrombocytopenia</strong>, fatigue, <strong>peripheral neuropathy</strong>, neutropenia, anaemia, anorexia, nausea, limb pain, dizziness, etc. Other adverse events like cardiac tamponade, disseminated intravascular coagulation, toxic epidermal necrolysis, etc. have been reported. </p>\n<p>Other options:</p>\n<p>Option B: <strong>Lenalidomide</strong> is the <strong>drug of choice</strong> in patients with <strong>myelodysplastic syndrome (MDS)</strong> associated with <strong>5q deletion</strong>, and is an <strong>immunomodulatory analogue</strong> of <strong>thalidomide</strong>. It <strong>suppresses bone marrow</strong> and is often associated with <strong>significant leukopenia</strong>.</p>\n<p>Option C: <strong>Daratumumab</strong> is a <strong>monoclonal antibody</strong> against <strong>CD-38</strong>. </p>\n<p>Option D: <strong>Elotuzumab</strong> is a <strong>monoclonal antibody</strong> against <strong>SLAMF7</strong>, a glycoprotein expressed in <strong>multiple myeloma cells </strong>and <strong>natural killer cells</strong>. It is used in <strong>combination</strong> with <strong>lenalidomide</strong> and <strong>dexamethasone</strong> for the treatment of <strong>multiple myeloma</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6588",
      "difficulty": "medium"
    },
    {
      "text": "A patient presented with breathing difficulty and nasal polyposis when he took aspirin for fever. He faced this issue previously too when he took aspirin. Which among the following is not true about this?<div class='question-desc-html'><p>COX -  Cyclooxygenase</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "There is no allergic sensitization to aspirin and its metabolites"
        },
        {
          "id": 2,
          "text": "Responds to Monteleukast "
        },
        {
          "id": 3,
          "text": "Occur on exposure to only aspirin"
        },
        {
          "id": 4,
          "text": "Occurs with exposure to other NSAIDs too that block COX 1"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The diagnosis for this patient with <strong>breathing difficulty</strong> and <strong>nasal polyposis</strong>, triggered by <strong>aspirin</strong>, a <strong>COX-1 inhibitor</strong> is <strong>aspirin-induced asthma</strong>, also known as <strong>Samter's triad</strong>. The statement that is not true is that \"it occurs on exposure to only aspirin\", as this condition can also be <strong>triggered</strong> by <strong>other NSAIDs</strong> that <strong>inhibit COX-1,</strong> and is <strong>not</strong> restricted to just <strong>aspirin alone</strong>.</p>\n<p><strong>Samter's triad </strong>is also known as <strong>aspirin-induced asthma </strong>or aspirin-sensitive asthma<strong>.</strong> It consists of:</p>\n<ul>\n<li><strong>Nasal polyposis</strong></li>\n<li>Bronchial <strong>asthma</strong></li>\n<li><strong>Aspirin intolerance</strong></li>\n</ul>\n<p>A patient with Samter's triad experiences severe asthma and nasal polyposis triggered by aspirin or other COX-1 inhibitors. This condition involves <strong>nasal congestion, rhinorrhea, anosmia,</strong> and <strong>recurrent chronic rhinosinusitis</strong>, with <strong>acute asthma attacks</strong> often occurring a few hours after ingestion of these medications.</p>\n<p>These patients <strong>overproduce leukotrienes</strong> due to COX-1 inhibition and <strong>decreased prostaglandin E2 (PGE2)</strong> levels. Therefore, they should <strong>avoid COX-1 inhibitors</strong> like aspirin and most NSAIDs but can generally<strong> tolerate COX-2 inhibitors</strong> and <strong>acetaminophen</strong>.</p>\n<p>Treatment typically includes <strong>leukotriene modifiers</strong>, and in some cases, <strong>aspirin desensitization</strong> may be used to manage symptoms and allow the use of aspirin or NSAIDs if necessary for other conditions. Recent advances in treatment include biologics such as <strong>Dupilumab</strong> and <strong>IL-5 inhibitors</strong>, which are increasingly effective in managing aspirin-induced asthma and may replace aspirin desensitization except when ongoing aspirin or NSAID therapy is required.</p>\n<p>Other options:</p>\n<p>Option A: The reaction in aspirin-induced asthma is <strong>not</strong> due to an <strong>allergic sensitization</strong> but rather due to the inhibition of COX-1 and subsequent overproduction of leukotrienes.</p>\n<p>Option B: <strong>Montelukast</strong>, a l<strong>eukotriene receptor antagonist,</strong> is effective in managing symptoms of aspirin-induced asthma by counteracting the elevated levels of leukotrienes that contribute to inflammation and respiratory issues.</p>\n<p>Option D: It occurs with exposure to other NSAIDs too, that block COX-1. Patients with aspirin-induced asthma can react to other <strong>NSAIDs </strong>that <strong>inhibit COX-1</strong>, not just aspirin. </p><hr><h3>Related Pearl: Extrinsic vs Intrinsic asthma</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Extrinsic asthma</strong></td>\n<td><strong>Intrinsic asthma</strong></td>\n</tr>\n<tr>\n<td>Other names</td>\n<td>Atopic/ allergic asthma</td>\n<td>Non-atopic/ non-allergic/ idiosyncratic asthma</td>\n</tr>\n<tr>\n<td>Associated with&nbsp;</td>\n<td>Atopy, drug or food allergy (past or family history)</td>\n<td>Samter&rsquo;s triad (asthma + aspirin sensitivity + sinus disease with recurrent nasal polyps)</td>\n</tr>\n<tr>\n<td>Onset</td>\n<td>Childhood</td>\n<td>Adult</td>\n</tr>\n<tr>\n<td>Inflammation</td>\n<td>Eosinophil mediated</td>\n<td>Neutrophil mediated</td>\n</tr>\n<tr>\n<td>IgE levels</td>\n<td>&uarr; IgE (type 1 hypersensitivity)</td>\n<td>Normal IgE (negative skin prick test)</td>\n</tr>\n<tr>\n<td>Most common trigger</td>\n<td>Dermatophagoides (House mite)</td>\n<td>\n<p>Superantigen -&nbsp;<br /><em>S. aureus</em> enterotoxin</p>\n</td>\n</tr>\n<tr>\n<td>Response to inhaled corticosteroids</td>\n<td>Responds well&nbsp;</td>\n<td>\n<p>Decreased short term response</p>\n</td>\n</tr>\n<tr>\n<td>Prognosis</td>\n<td>Good</td>\n<td>Bad</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6745",
      "difficulty": "medium"
    },
    {
      "text": "A 75-year-old female presented with urinary incontinence. She also has cognition decline and dementia. Which of the following drugs is useful for treating urinary incontinence?",
      "choices": [
        {
          "id": 1,
          "text": "Tiotropium\t"
        },
        {
          "id": 2,
          "text": "Ipratropium\t"
        },
        {
          "id": 3,
          "text": "Tolterodine\t"
        },
        {
          "id": 4,
          "text": "Telenzipine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>For managing <strong>urinary incontinence</strong> in a 75-year-old female with <strong>cognitive decline</strong> and <strong>dementia</strong>, <strong>tolterodine</strong> is useful.</p>\n<p>Tolterodine is a <strong>muscarinic receptor antagonist</strong> specifically effective for treating urinary incontinence. It exhibits selectivity for the urinary bladder, which helps to minimize side effects compared to other antimuscarinic agents. This selectivity is <strong>beneficial</strong> for patients with <strong>cognitive decline </strong>or dementia, as it <strong>reduces </strong>the risk of <strong>adverse effects.</strong> Tolterodine is <strong>metabolized</strong> by <strong>CYP2D6</strong>, so its dosage may need adjustment based on individual CYP2D6 activity, making it a suitable option for managing urinary incontinence while minimizing potential side effects.</p>\n<p>Other muscarinic antagonists for urinary incontinence include <strong>oxybutynin, trospium chloride, darifenacin, solifenacin</strong>, and <strong>fesoterodine</strong>. <strong>Oxybutynin</strong>, though effective, often causes antimuscarinic side effects such as <strong>xerostomia</strong>. <strong>Trospium</strong> chloride, being a quaternary amine, is better tolerated and <strong>excreted primarily</strong> via the<strong> kidneys</strong>, requiring dosage adjustments in renal impairment. <strong>Darifenacin</strong> and <strong>solifenacin</strong> have selectivity for<strong> M3 receptors</strong>, which helps balance efficacy and side effects, while <strong>fesoterodine</strong>, a <strong>prodrug</strong>, provides a stable pharmacokinetic profile due to its <strong>conversion</strong> to <strong>tolterodine’s active metabolite</strong>.</p>\n<p>Other Options:</p>\n<p>Option A: <strong>Tiotropium</strong> and Option C: <strong>Ipratropium</strong> are <strong>muscarinic antagonists</strong> used primarily for respiratory conditions such as <strong>chronic obstructive pulmonary disease (COPD)</strong> and <strong>asthma</strong>, rather than urinary incontinence. <strong>Tiotropium</strong> is a <strong>long</strong>-acting agent with selectivity for <strong>M1 </strong>and <strong>M3</strong> receptors, while <strong>Ipratropium</strong> is used more frequently for its<strong> short</strong>-acting effects.</p>\n<p>Option D: <strong>Telenzepine</strong>, an <strong>analogue</strong> of <strong>Pirenzepine</strong>, displays higher potency and selectivity for <strong>M1</strong> receptors compared to pirenzepine and is used in treating <strong>acid-peptic diseas</strong>e, not urinary incontinence. </p><hr><h3>Related Pearl: Muscarinic antagonists indicated for detrusor instability/overactive bladder</h3><table>\n<tbody>\n<tr>\n<td><strong>Mechanism/Feature</strong></td>\n<td><strong>Drug</strong></td>\n</tr>\n<tr>\n<td>Direct smooth muscle relaxant &nbsp;</td>\n<td>\n<p>Flavoxate</p>\n<p>Oxybutynin</p>\n</td>\n</tr>\n<tr>\n<td>Bladder selective &nbsp;</td>\n<td>\n<p>Tolterodine</p>\n<p>Fesoterodine (prodrug)</p>\n</td>\n</tr>\n<tr>\n<td>Only quaternary compound &nbsp;</td>\n<td>Trospium</td>\n</tr>\n<tr>\n<td>M3 selective &nbsp;</td>\n<td>\n<p>Darifenacin</p>\n<p>Solifenacin</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6781",
      "difficulty": "medium"
    },
    {
      "text": "A 7-year-old boy presents with a two-week history of persistent fever, fatigue, and pallor. His parents also report easy bruising and gum bleeding. On examination, he is pale with petechiae on his legs, hepatosplenomegaly, and generalized lymphadenopathy. Blood tests show severe anemia, thrombocytopenia, and elevated white blood cell count with blast cells. What is the most appropriate initial treatment regimen for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "IVIG"
        },
        {
          "id": 2,
          "text": "Doxorubicin + Idarubicin "
        },
        {
          "id": 3,
          "text": "Prednisolone + vincristine"
        },
        {
          "id": 4,
          "text": "Radiotherapy of lymph nodes"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario suggests a diagnosis of <strong>Acute Lymphoblastic Leukemia </strong>(ALL), and standard initial treatment in children includes a chemotherapy regimen with drugs like <strong>prednisolone</strong> and <strong>vincristine</strong> during the<strong> induction phase</strong>. </p>\n<p>Patients diagnosed with ALL present with symptoms of<strong> impaired marrow function</strong> like <strong>anaemia, infections</strong> secondary to neutropenia, and <strong>bleeding</strong> due to thrombocytopenia. Other symptoms include <strong>bone pain</strong>, generalized lymphadenopathy, splenomegaly, hepatomegaly, testicular enlargement, headache, vomiting, and nerve palsies.</p>\n<p>Treatment of ALL</p>\n<p><strong>Induction:</strong> L-Asparaginase, vincristine, prednisolone, and anthracycline<br /><strong>CNS prophylaxis </strong>with intrathecal methotrexate<br /><strong>Consolidation:</strong> Methotrexate, cytarabine <br /><strong>Maintenance:</strong> 6-Mercaptopurine, methotrexate plus intrathecal therapy</p>\n<p>Other Options:</p>\n<p>Option A: IVIG: Intravenous immunoglobulin (IVIG) is <strong>not</strong> used for treating ALL.</p>\n<p>option B: Both <strong>doxorubicin</strong> and <strong>idarubicin</strong> <strong>are</strong> <strong>anthracyclines</strong> used in chemotherapy. While doxorubicin can be part of certain ALL treatment protocols, idarubicin is more commonly used in Acute Myeloid Leukemia (AML) rather than ALL. This combination is not typically used in the induction phase for ALL children.</p>\n<p>Option D: Radiotherapy is <strong>not</strong> a standard initial treatment for ALL. It may be considered in specific cases, such as central nervous system involvement or certain high-risk cases, but the primary treatment for ALL is systemic chemotherapy, not localized radiotherapy.</p><hr><h3>Related Pearl: Morphological Characteristics of Blasts Cells in Acute Lymphoblastic Leukemia vs. Acute Myeloid Leukemia</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Lymphoblasts&nbsp;</strong></td>\n<td><strong>Myeloblasts</strong>&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Blast population</strong></td>\n<td>Homogeneous</td>\n<td>Heterogeneous,&nbsp;with the exception of&nbsp;the undifferentiated form&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Size</strong></td>\n<td>Variable, mainly small&nbsp;</td>\n<td>Variable, mainly large&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Nucleus</strong></td>\n<td>Central, mainly round; sometimes indented.&nbsp;<br />&nbsp;</td>\n<td>Eccentric, round, oval, or angulated; sometimes convoluted, particularly in the form with a monocytic component&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Chromatin</strong></td>\n<td>Fine, with dispersed condensation.&nbsp;<br />Very condensed in small&nbsp;lymphoblasts&nbsp;</td>\n<td>Fine, granular, delicately dispersed&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Nucleoli</strong></td>\n<td>Absent in small&nbsp;lymphoblasts.&nbsp;<br />Sometimes indistinct&nbsp;</td>\n<td>Present. Often large and prominent,&nbsp;double or triple&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Cytoplasm</strong></td>\n<td>Scanty and basophilic.<br />Sometimes with a single long projection (hand-mirror cell)&nbsp;</td>\n<td>Variable.&nbsp;<br />Abundant in&nbsp;monoblasts,&nbsp;<br />with protrusions in erythroblasts and&nbsp;megakaryoblasts&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Granules</strong></td>\n<td>Rarely present. Negative for peroxidase,&nbsp;esterases, and toluidine blue&nbsp;</td>\n<td>Present&nbsp;in forms with differentiation and positive with cytochemical stains\n<ul>\n<li data-listid=\"35\" data-aria-posinset=\"1\" data-aria-level=\"1\">Peroxidase in the neutrophil and&nbsp;eosinophil&nbsp;lineages</li>\n<li data-listid=\"35\" data-aria-posinset=\"2\" data-aria-level=\"1\">Nonspecific esterase in the monocyte lineage&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Auer rods</strong></td>\n<td>Absent&nbsp;</td>\n<td>Can be present.&nbsp;<br />Typically present in the hyper granular promyelocytic form&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Vacuoles</strong></td>\n<td>Can&nbsp;be present</td>\n<td>Can be present.&nbsp;<br />Almost always present in forms with a monocytic component&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The image given below shows lymphoblasts.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/602336fa8d4c493297f9396f1c0723d3x720x820.JPEG\" alt=\"Pearl Image\"><p>The image given below shows myeloblasts.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b1dfcd5c07f949719ccdce6583872615x250x364.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Prognostic Factors in Acute Lymphoblastic Leukemia (ALL)</h3><table>\n<tbody>\n<tr>\n<td><strong>Good prognostic markers&nbsp;</strong></td>\n<td><strong>Bad prognostic markers&nbsp;</strong></td>\n</tr>\n<tr>\n<td>Age between 2 and 10 years&nbsp;</td>\n<td>\n<p>Age younger than 2 years&nbsp;</p>\n<p>Presentation in adolescence or adulthood</p>\n</td>\n</tr>\n<tr>\n<td>Low white cell count&nbsp;</td>\n<td>Peripheral blood blast counts greater than 100,000,</td>\n</tr>\n<tr>\n<td>Female&nbsp;</td>\n<td>Male&nbsp;</td>\n</tr>\n<tr>\n<td>Hyperdiploidy&nbsp;</td>\n<td><span class=\"TextRun SCXW19478924\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW19478924\">Hypodiploidy</span></span><span class=\"EOP SCXW19478924\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span>&nbsp;</td>\n</tr>\n<tr>\n<td>Trisomy of chromosomes 4, 7, 10 &amp; 17</td>\n<td> Pseudodiploidy&nbsp;or t (9;22)&nbsp;&nbsp;or t (8;14) or t (4;11)&nbsp;</td>\n</tr>\n<tr>\n<td>&nbsp;<span class=\"TextRun SCXW77923760\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW77923760\">t (12;21)<span class=\"EOP SCXW77923760\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></span></span></td>\n<td><em>MLL</em> gene rearrangements&nbsp;</td>\n</tr>\n<tr>\n<td>Early precursor B cell phenotype</td>\n<td>&nbsp;T cell phenotype</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6725",
      "difficulty": "medium"
    },
    {
      "text": "Lignocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?",
      "choices": [
        {
          "id": 1,
          "text": "Clearance "
        },
        {
          "id": 2,
          "text": "Volume of distribution"
        },
        {
          "id": 3,
          "text": "Plasma half life"
        },
        {
          "id": 4,
          "text": "Bioavailability"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>volume of distribution</strong> of the drug <strong>determines</strong> the<strong> loading dose</strong> of the drug.</p>\n<p><strong>Loading Dose</strong> = <strong>Volume of distribution</strong> x <strong>Desired steady-state plasma concentration</strong>.</p>\n<p>When the time to reach a steady-state is long, as it is for <strong>drugs</strong> with <strong>long half-lives,</strong> it may be desirable to <strong>administer</strong> a <strong>loading dose</strong> that promptly raises the concentration of the drug in plasma to the target concentration.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Clearance</strong> is used to determine the <strong>maintenance dose</strong>. </p>\n<p>Maintenance dose = clearance x desired steady-state plasma concentration.</p>\n<p>Options C and D: Plasma <strong>half-life</strong> primarily <strong>determines</strong> the <strong>frequency</strong> of dosing, while <strong>bioavailability</strong> <strong>determines</strong> the <strong>route</strong> of administration. Though bioavailability may affect the dose necessary, it will not be the primary factor considered during the calculation of the loading dose.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6709",
      "difficulty": "easy"
    },
    {
      "text": "A hypertensive patient with chronic kidney disease was having frequent attacks of renal colic. Which of the following diuretics is used? ",
      "choices": [
        {
          "id": 1,
          "text": "Furosemide\t"
        },
        {
          "id": 2,
          "text": "Mannitol"
        },
        {
          "id": 3,
          "text": "Hydrochlorothiazide\t"
        },
        {
          "id": 4,
          "text": "Spironolactone"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>For a <strong>hypertensive</strong> patient with <strong>chronic kidney disease</strong> experiencing frequent attacks of <strong>renal colic</strong>, <strong>hydrochlorothiazide</strong>, a <strong>thiazide diuretic</strong>, is often used.</p>\n<p><strong>Thiazide diuretics</strong> are particularly effective in cases of <strong>calcium oxalate kidney stones</strong> because they <strong>reduce urinary calcium excretion</strong>. They work by acting on the <strong>distal convoluted tubule (DCT)</strong> of the nephron, where they<strong> inhibit</strong> the <strong>Na+/Cl- co-transporter</strong>. This <strong>inhibition decreases</strong> the <strong>intracellular sodium concentration</strong>, which, through compensatory mechanisms, leads to<strong> increased calcium reabsorption</strong> into the bloodstream.</p>\n<p>While this mechanism helps in <strong>decreasing urinary calcium</strong> and <strong>managing calcium oxalate stones</strong>, thiazide diuretics can also cause <strong>adverse effects</strong> such as <strong>hypokalemia</strong>, <strong>hyperuricemia</strong>, and <strong>hypercalcemia</strong>. The <strong>increased reabsorption</strong> of <strong>uric acid</strong> due to the diuretic effect can exacerbate conditions like <strong>gout</strong> and should be monitored carefully.</p>\n<p>In addition to their use in treating calcium oxalate kidney stones, thiazide diuretics are commonly prescribed for managing <strong>uncomplicated hypertension</strong> and treating <strong>edema</strong> associated with <strong>heart, liver</strong>, and <strong>kidney</strong> diseases. They are also used for conditions like <strong>osteoporosis</strong> and <strong>nephrogenic diabetes insipidus</strong>. </p>\n<p>Other options:</p>\n<p>Option A: <strong>Furosemide</strong> is a <strong>diuretic</strong> that can <strong>increase calcium excretion</strong>, potentially <strong>raising PTH </strong>as the body tries to conserve calcium.</p>\n<p>Option B: <strong>Osmotic diuretics</strong>, like <strong>mannitol</strong>,<strong> retain water</strong> isoosmotically in the <strong>proximal convoluted tubule (PCT)</strong> and <strong>descending loop of Henle</strong> which are freely permeable to water. Luminal fluid is diluted and opposes NaCl reabsorption and promotes calcium excretion. They are indicated in <strong>raised intracranial tension</strong> and in <strong>dialysis disequilibrium</strong>.</p>\n<p>Option D: <strong>Spironolactone</strong> is a <strong>potassium-sparing diuretic</strong> and <strong>aldosterone antagonist</strong>. It works by <strong>competitively inhibiting aldosterone receptors</strong> in the distal tubules of the kidney.</p><hr><h3>Related Pearl: Effect of diuretics on excretion of electrolytes</h3><table>\n<tbody>\n<tr>\n<td><strong>Diuretics</strong></td>\n<td><strong>Sodium</strong></td>\n<td><strong>Potassium</strong></td>\n<td><strong>Calcium</strong></td>\n</tr>\n<tr>\n<td><strong>Carbonic anhydrase inhibitors</strong></td>\n<td>&uarr;</td>\n<td>&uarr;&uarr;</td>\n<td>No change</td>\n</tr>\n<tr>\n<td><strong>Osmotic diuretics</strong></td>\n<td>&uarr;&uarr;</td>\n<td>&uarr;</td>\n<td>&uarr;</td>\n</tr>\n<tr>\n<td><strong>Loop diuretics</strong></td>\n<td>&uarr;&uarr;</td>\n<td>&uarr;&uarr;</td>\n<td>&uarr;&uarr;</td>\n</tr>\n<tr>\n<td><strong>Thiazides</strong></td>\n<td>&uarr;</td>\n<td>&uarr;&uarr;</td>\n<td>&darr;</td>\n</tr>\n<tr>\n<td><strong>Epithelial sodium channel blockers</strong></td>\n<td>&uarr;</td>\n<td>&darr;</td>\n<td>&darr;</td>\n</tr>\n<tr>\n<td><strong>Aldosterone antagonists</strong></td>\n<td>&uarr;</td>\n<td>&darr;</td>\n<td>Insufficient data</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Acute effects of thiazides on Ca<sup>2+</sup> excretion are variable but when administered chronically, it decreases Ca<sup>2+</sup> excretion.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6714",
      "difficulty": "medium"
    },
    {
      "text": "Identify the drug marked as 'X' in the image.<div class='question-desc-html'><p>tPA - Tissue Plasminogen Activator</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Clopidogrel \t"
        },
        {
          "id": 2,
          "text": "Amino caproic acid"
        },
        {
          "id": 3,
          "text": "Tenecteplase\t"
        },
        {
          "id": 4,
          "text": "Heparin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug marked as 'X' in the image is <strong>aminocaproic acid.</strong></p>\n<p><strong>ε-Aminocaproic acid</strong>, a <strong>lysine analogue</strong> that competes with <strong>plasminogen</strong> for <strong>binding sites</strong> on <strong>fibrin</strong>. By blocking this interaction, ε-Aminocaproic acid <strong>prevents</strong> the conversion of <strong>plasminogen</strong> into <strong>plasmin</strong>, thereby <strong>inhibiting fibrinolysis</strong>. This action makes it a useful agent for <strong>reversing</strong> the effects of <strong>fibrinolytic therapy</strong>.</p>\n<p>However, ε-Aminocaproic acid should be administered with caution as it can <strong>suppress intrinsic fibrinolytic activity</strong>, potentially leading to complications such as <strong>disseminated intravascular coagulation (DIC)</strong>. To address this, <strong>fresh frozen plasma</strong> and <strong>cryoprecipitate</strong> may be used to restore fibrin and clotting factors.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/eaf426b95b65411ab20b432201766924x1280x1403.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Plasminogen activators (classification of fibrinolytics)</h3><p><strong>Fibrin non-specific</strong> plasminogen activators</p>\n<ul>\n<li>Streptokinase - least fibrin specific and has the lowest incidence of intracranial hemorrhage</li>\n<li>Anistreplase</li>\n<li>Urokinase</li>\n</ul>\n<p><strong>Fibrin specific</strong> plasminogen activators</p>\n<ul>\n<li>Alteplase - has the shortest half-life</li>\n<li>Tenecteplase - most fibrin specific and given as a single bolus dose</li>\n<li>Reteplase</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/027728f8da6746d1b3504b71d1062798.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6711",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following beta-adrenergic blockers are beneficial for patients with reduced ejection fraction and can reduce mortality in chronic heart failure without causing exacerbations over a few years?",
      "choices": [
        {
          "id": 1,
          "text": "Propanolol"
        },
        {
          "id": 2,
          "text": "Pindolol "
        },
        {
          "id": 3,
          "text": "Esmolol"
        },
        {
          "id": 4,
          "text": "Bisoprolol"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>beta-adrenergic blocker</strong> that is useful in patients with <strong>reduced ejection fraction a</strong>nd can<strong> reduce mortality </strong>in <strong>chronic heart failure </strong>without causing exacerbations over a few years is <strong>bisoprolol.</strong></p>\n<p><strong>Bisoprolol</strong> is preferred for use in patients having <strong>heart failure with reduced ejection fraction (HFrEF)</strong>.</p>\n<p>The <strong>exacerbation</strong> mentioned in the context of <strong>beta-blockers</strong> for heart failure refers to the potential <strong>worsening</strong> of <strong>heart failure symptoms</strong> in some patients, despite the overall benefits of these medications. They can sometimes lead to a<strong> decline</strong> in <strong>left ventricular function</strong>, particularly in individuals with <strong>limited cardiac reserve</strong> who rely heavily on <strong>adrenergic stimulation</strong>. This deterioration can manifest as <strong>increased heart failure symptoms</strong> or a <strong>decrease</strong> in <strong>cardiac function</strong>. The <strong>only beta-blockers</strong> that have been proven to<strong> improve</strong> the <strong>survival</strong> of patients with <strong>HFrEF</strong> or <strong>chronic HF</strong> are -</p>\n<ul>\n<li><strong>B</strong>isoprolol</li>\n<li><strong>M</strong>etoprolol</li>\n<li><strong>C</strong>arvedilol</li>\n</ul>\n<p><strong>HFrEF</strong> is a complex clinical syndrome where the ventricle fails to adequately fill with or eject blood, typically defined by an <strong>ejection fraction (EF) less than or equal to 40%</strong>. Key etiologies include <strong>coronary artery disease, valvular heart disease, congenital heart diseases, and autoimmune diseases like giant cell myocarditis</strong>. Patients with HFrEF commonly experience symptoms like <strong>dyspnea on exertion</strong>, orthopnea, and paroxysmal nocturnal dyspnea, and may present with <strong>pedal edema</strong>, elevated jugular venous pressure (JVP), ascites, and hepatomegaly on examination.</p>\n<p>The pharmacological <strong>management</strong> of HFrEF involves drugs with both <strong>symptomatic</strong> and <strong>mortality benefits</strong>, including <strong>Angiotensin receptor–neprilysin inhibitors (ARNIs)</strong> such as sacubitril/valsartan, angiotensin-converting enzyme <strong>(ACE) inhibitors</strong> like ramipril and enalapril, β-blockers such as metoprolol and carvedilol, mineralocorticoid receptor antagonists like spironolactone and eplerenone,<strong> sodium-glucose cotransporter 2 (SGLT2) inhibitors </strong>like dapagliflozin, and hydralazine plus isosorbide dinitrate (noting a mortality benefit specifically in African-American patients). Drugs used primarily for<strong> symptomatic relief</strong>, such as <strong>loop diuretics</strong> (e.g., furosemide), and digoxin, are reserved for specific indications or during decompensation. <strong>Non-pharmacological </strong>therapies for HFrEF include <strong>implantable cardioverter-defibrillators (ICD) </strong>and <strong>cardiac resynchronization therapy.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6589",
      "difficulty": "medium"
    },
    {
      "text": "Which drug is used for maintenance therapy in opium addiction?<br><br>",
      "choices": [
        {
          "id": 1,
          "text": "Buprenorphine "
        },
        {
          "id": 2,
          "text": "Naloxone "
        },
        {
          "id": 3,
          "text": "Butarphanol"
        },
        {
          "id": 4,
          "text": "Clonidine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The drug used among the following options for <strong>maintenance therapy</strong> in <strong>opium addiction</strong> is <strong>buprenorphine.</strong></p>\n<p>Buprenorphine is a <strong>partial μ-opioid agonist</strong> and an <strong>antagonist</strong> at <strong>δ </strong>and <strong>κ receptors</strong>. It is widely used both as an <strong>analgesic</strong> for <strong>chronic pain conditions</strong>, such as cancer pain, and as a treatment for <strong>opioid dependence</strong>, serving as an <strong>alternative </strong>to <strong>methadone</strong>.</p>\n<p>It effectively <strong>controls cravings</strong> and<strong> blocks </strong>the <strong>effects</strong> of <strong>higher-efficacy opioids</strong>. It is often administered in <strong>combination</strong> with <strong>naloxone</strong> to <strong>prevent misuse</strong>, although it may be given <strong>alone</strong> to <strong>pregnant women</strong> or individuals with <strong>naloxone allergies</strong>. Initial dosing typically starts at <strong>2-4 mg daily</strong>, with adjustments made to stabilize the dose at approximately <strong>12 to 16 mg/day</strong>. </p>\n<p>For opioid use disorder, effective management includes both <strong>withdrawal </strong>and <strong>long-term treatment</strong> strategies. Withdrawal and detoxification generally start with <strong>managing physical dependence</strong> using medications like <strong>methadone </strong>or <strong>buprenorphine</strong>. <strong>Methadone</strong>, a <strong>full agonist</strong>, is used to stabilize and reduce withdrawal symptoms, while <strong>buprenorphine</strong> helps with cravings and has a <strong>lower risk</strong> of <strong>overdose</strong>.</p>\n<p><strong>Clonidine</strong> and <strong>lofexidine</strong>, <strong>alpha-2 agonists,</strong> are used to <strong>ameliorate withdrawal symptoms</strong>. Lofexidine, approved by the FDA, is the <strong>first non-opioid treatment</strong> specifically for <strong>opioid withdrawal </strong>in adults. <strong>Naltrexone</strong>, a long-acting opioid antagonist, is used as an adjunct in patients who are already <strong>opioid-free</strong>; however, it will <strong>precipitate acute withdrawal symptoms</strong> if administered to those still <strong>dependent</strong> on opioids.</p><hr><h3>Related Pearl: Substances of abuse</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Substance</strong></span></div>\n</td>\n<td>\n<div><span><strong>Withdrawal symptoms</strong></span></div>\n</td>\n<td>\n<div><span><strong>Intoxication features</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Alcohol</strong></span></div>\n</td>\n<td>\n<div><span>Tremors, delirium, seizures</span></div>\n</td>\n<td>\n<div><span>Blackouts, nystagmus and slurring of speech</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>BZD</strong></span></div>\n</td>\n<td>\n<div><span>Tremors,&nbsp;insomnia, anxiety</span></div>\n</td>\n<td>\n<div><span>Lethargy and drowsiness.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Opioid/ Heroin</strong></span></div>\n</td>\n<td>\n<div><span>Diarrhea,&nbsp;yawning, mydriasis,&nbsp;lacrimation, piloerection, cold turkey phenomenon</span></div>\n</td>\n<td>\n<div><span>Euphoria, depressed mental status, miosis, respiratory depression, constipation.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Nicotine/ Tobacco</strong></span></div>\n</td>\n<td>\n<div><span>Increased appetite</span></div>\n</td>\n<td>\n<div><span>Shows a biphasic pattern.&nbsp;</span></div>\n<div><span>Early stimulatory symptoms of vomiting, hypertension and tachycardia.&nbsp;</span><span>Later depressive symptoms of hypotension and bradycardia.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Cannabis</strong></span></div>\n</td>\n<td>\n<div><span>Irritability, sweating, tremors, decreased appetite</span></div>\n</td>\n<td>\n<div><span>Increased appetite, euphoria, conjunctival injection, dry mouth,&nbsp;</span><span>panic,&nbsp;</span><span>synesthesia, impaired time perception, amotivational&nbsp;syndrome, run amok and&nbsp;</span><span>flashbacks.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Amphetamine</strong></span></div>\n</td>\n<td>\n<div><span>Depressed mood, suicidal thoughts, unpleasant dreams</span></div>\n</td>\n<td>\n<div>\n<div><span>Acute:&nbsp;</span><span>Sympathetic&nbsp;</span><span>overactivity, paranoid hallucinatory syndrome, violent behavior, psychosis and diaphoresis.</span></div>\n</div>\n<div><span>Chronic: Runs &amp; crashes, choreiform movements, tooth decay. Can resemble schizophrenia.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Cocaine</strong></span></div>\n</td>\n<td>\n<div><span>Depressed mood, suicidal thoughts</span></div>\n</td>\n<td>\n<div><span>Acute: Sympathetic overactivity, agitation, euphoria, chest pain, seizures and mydriasis</span></div>\n<div><span>Chronic: Cocaine psychosis (Magnan sign) and black pigmentation of the tongue.</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>LSD/ Haluccinogen</strong></span></div>\n</td>\n<td>\n<div><span>Nothing significant</span></div>\n</td>\n<td>\n<div>\n<div><span>Synesthesia, brisk tendon reflex, t</span>achycardia, hypertension, panic, ataxia, visual hallucinations, euphoria and dysphoria.</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Phencyclidine (PCP)</strong></span></div>\n</td>\n<td>\n<div><span>Nothing significant&nbsp;</span></div>\n</td>\n<td>\n<div>Tachycardia, hypertension, ataxia, hallucinations, violent behavior, dissociation, amnesia and nystagmus.</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6590",
      "difficulty": "medium"
    },
    {
      "text": "A patient who recently underwent surgery has complaints of nausea and vomiting. He was prescribed a drug called aprepitant. What is its mechanism of action?\t",
      "choices": [
        {
          "id": 1,
          "text": "NK-3 antagonist\t"
        },
        {
          "id": 2,
          "text": "NK-2 agonist"
        },
        {
          "id": 3,
          "text": "NK-1 antagonist"
        },
        {
          "id": 4,
          "text": "NK-1 agonist"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The class of drugs <strong>most preferred</strong> in patients suffering from <strong>postoperative nausea and vomiting (PONV)</strong>, following surgery are the <strong>NK1 antagonists </strong>like <strong>aprepitant.</strong></p>\n<p><strong>Substance P </strong>is a neuropeptide that interacts with neurokinin-1 (NK-1) receptors. <strong>NK1 antagonists</strong> inhibit substance P at central and peripheral receptors. <strong>Aprepitant, fosaprepitant are examples of</strong> NK1 antagonists. It also acts on the chemotrigger zone whose location is shown below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/412d569ccab6464c923b959231b29e98x512x371.PNG\" alt=\"Explanation Image\"><p>PONV Physiology: <span><strong>Afferents</strong> from the <strong>chemoreceptor trigger zone </strong>(CTZ), <strong>vagal neurons</strong> in the gastrointestinal system, neurons from the vestibular system and midbrain afferents <strong>relay</strong> within the <strong>vomiting centre</strong> in the reticular formation of the brainstem which then project into the <strong>nucleus tractus solitarius</strong>.</span></p>\n<p><strong>Risk factors</strong> for PONV are divided into:</p>\n<ul>\n<li>Patient factors\n<ul>\n<li><strong>Female</strong>&gt;male</li>\n<li>Age<strong>&lt;50 years</strong></li>\n<li>Prior history of <strong>motion sickness</strong></li>\n<li><strong>Non-smokers</strong> &gt; smokers (<strong>CTZ</strong> is <strong>desensitized</strong>)</li>\n</ul>\n</li>\n<li>Preoperative factors\n<ul>\n<li>(<strong>Fasting </strong>and <strong>anxiety</strong>, while possibly contributing to PONV, have yet to be demonstrated)</li>\n</ul>\n</li>\n<li>Intraoperative factors\n<ul>\n<li>Surgical - <strong>Cholecystectomy, gynaecological</strong> and <strong>laparoscopic</strong> procedures have higher incidences</li>\n<li>Drugs - <strong>Nitrous oxide</strong>, <strong>Opioids</strong>, Cyclopropane,</li>\n<li><strong>General anaesthesia</strong> has a times <strong>more risk</strong> of developing PONV than regional anaesthesia.</li>\n</ul>\n</li>\n<li>Postoperative factors\n<ul>\n<li><strong>Pain</strong> and <strong>early ambulatio</strong>n contribute to a higher risk of PONV.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Scoring systems </strong>used to grade PONV are<strong> </strong>the<strong> Apfel score </strong>and the<strong> Koivuranta score.</strong></p>\n<p>Drugs used in the <strong>prophylaxis</strong> and treatment of PONV:</p>\n<ul>\n<li>5-HT 3 antagonists - <strong>ondansetron</strong>, palonosetron</li>\n<li>Butyrophenones- <strong>droperidol</strong></li>\n<li><strong>Dexamethasone</strong></li>\n<li>Transdermal scopolamine</li>\n<li><strong>Aprepitant</strong></li>\n</ul>\n<p>Note:<strong> Double-blind studies</strong> have found <strong>no difference</strong> in the efficacy between <strong>aprepitant(NK1 antagonists)</strong> and <strong>ondansetron (5HT3 antagonist)</strong> in the <strong>first 24 hours</strong> following surgery. But <strong>after 24 hours</strong> <strong>aprepitant</strong> has proven to be <strong>more productive</strong> than ondansetron in the management of <strong>PONV</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6591",
      "difficulty": "easy"
    },
    {
      "text": "An HIV patient developed a fever and dry cough. He was diagnosed with TB. He is currently on Lamivudine, Zidovudine and Nevirapine. Which Anti -TB drug should be changed in this patient?<div class='question-desc-html'><p>TB-Tuberculosis</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Isoniazid"
        },
        {
          "id": 2,
          "text": "Rifampicin"
        },
        {
          "id": 3,
          "text": "Streptomycin"
        },
        {
          "id": 4,
          "text": "Ethambutol"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Rifampicin </strong>should be avoided as it is a potent<strong> inducer </strong>of<strong> CYP enzymes </strong>including CYPs 1A2, 3A4, 2C9, and 2C19, which in turn can <strong>induce </strong>the<strong> metabolism </strong>of<strong> nevirapine</strong> and results in <strong>therapeutic failure </strong>of <strong>ART.</strong></p>\n<p><strong>Rifabutin </strong>causes the <strong>least induction</strong> of cytochrome enzymes and is therefore <strong>preferred in HIV patients</strong> who are on<strong> protease inhibitors/NNRTIs.</strong></p>\n<p>Cytochrome enzyme-inducing potency of rifamycins is <strong>rifampicin &gt; rifapentine &gt; rifabutin.</strong></p>\n<p>Note: </p>\n<table>\n<tbody>\n<tr>\n<td>Cytochrome p-450 inducers</td>\n<td>Cytochrome p-450 inhibitors</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Barbiturates</li>\n<li>Carbamazepine</li>\n<li>Rifampin</li>\n<li>Phenytoin</li>\n<li>Aminoglutethimide</li>\n<li>Cigarette smoking</li>\n<li>Chronic alcoholism</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Macrolide antibiotics</li>\n<li>Azole antifungals</li>\n<li>Chloramphenicol</li>\n<li>Omeprazole</li>\n<li>Selective serotonin reuptake inhibitors (SSRIs)</li>\n<li>HIV protease inhibitors</li>\n<li>Cimetidine</li>\n<li>Ciprofloxacin</li>\n<li>Metronidazole</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Cytochrome enzyme inducing potency of Rifamycins</h3><ul>\n<li>Rifampicin: Highest </li>\n<li>Rifapentine: Intermediate </li>\n<li>Rifabutin: Least</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG7224",
      "difficulty": "easy"
    },
    {
      "text": "A 32-year-old woman diagnosed with diarrhoea-predominant irritable bowel syndrome presented to the casualty with severe abdominal pain. She was prescribed a drug that exerts a direct spasmolytic effect on the smooth muscles of the gastrointestinal tract. Which drug could it be?",
      "choices": [
        {
          "id": 1,
          "text": "Dicyclomine"
        },
        {
          "id": 2,
          "text": "Scopolamine"
        },
        {
          "id": 3,
          "text": "Galantamine"
        },
        {
          "id": 4,
          "text": "Rivastigmine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Dicyclomine</strong> is a weak muscarinic receptor antagonist with non-specific <strong>direct spasmolytic</strong> effects on the smooth muscle of the gastrointestinal tract.</p>\n<p>Other options:</p>\n<p>Option B: <strong>Scopolamine</strong> exerts <strong>spasmolytic activity</strong> indirectly through its <strong>antimuscarinic action</strong>. It is not preferred due to its adverse effects like drowsiness, dryness, and blurred vision. </p>\n<p>Option C and D: <strong>Galantamine</strong> and <strong>rivastigmine</strong> are <strong>central cholinesterase inhibitors</strong> and do not possess spasmolytic activity.</p><hr><h3>Related Pearl: Drugs used in irritable bowel syndrome (IBS)</h3><p>For abdominal pain</p>\n<ul>\n<li>Antispasmodics - Dicyclomine</li>\n<li>Tricyclic antidepressants - Amitriptyline, Imipramine</li>\n<li>Selective serotonin reuptake inhibitor - Citalopram</li>\n</ul>\n<p>For diarrhoea</p>\n<ul>\n<li>Opiate - Loperamide</li>\n<li>5-HT3 antagonist - Alosetron</li>\n<li>Bile acid sequestrant - Cholestyramine resin</li>\n</ul>\n<p>For constipation</p>\n<ul>\n<li>Laxatives such as psyllium/ispaghula husk and polyethylene glycol</li>\n<li>Cl<sup>-</sup> channel activator - Lubiprostone</li>\n<li>Guanylate cyclase agonist - Linaclotide</li>\n<li>5-HT4 agonist - Tegaserod</li>\n<li>Selective serotonin reuptake inhibitor - Paroxetine</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG7222",
      "difficulty": "easy"
    },
    {
      "text": "A patient is started on a 3 HP TPT regimen. Which of the following is true regarding the regimen? <div class='question-desc-html'><p>TPT - Tuberculosis Preventative Therapy</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "There is more compliance in 3HP than 9H and 6H"
        },
        {
          "id": 2,
          "text": "No significant difference in 3HP, 6H, 9H"
        },
        {
          "id": 3,
          "text": "Chance of abortion in 3 HP is same as 6H"
        },
        {
          "id": 4,
          "text": "3HP regimen is less effective than 6H and 9H in preventing active TB"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The 3HP regimen, which involves <strong>once-weekly</strong> doses of <strong>Isoniazid</strong> and <strong>Rifapentine</strong> for <strong>12</strong> <strong>weeks</strong>, has been found to have <strong>higher patient compliance</strong> than the <strong>9-month</strong> regimen of <strong>Isoniazid (9H)</strong> and the <strong>6-month regimen (6H).</strong></p>\n<p>The <strong>shorter duration</strong> and <strong>reduced number</strong> of <strong>doses</strong> in the 3HP regimen make it more <strong>convenient</strong> and thus lead to better <strong>adherence.</strong> Studies have shown that patients are more likely to complete the 3HP regimen due to the shorter treatment duration and lower pill burden.</p>\n<p>TPT stands for <strong>Tuberculosis Preventive Therapy.</strong> It is a treatment given to individuals who are at <strong>high risk</strong> of <strong>developing active tuberculosis</strong> (TB) to prevent the progression from latent TB infection (where the person is infected with the TB bacteria but does not have symptoms) to active TB disease.</p>\n<p>There are different regimens for TPT, including:</p>\n<ul>\n<li>3HP: A regimen consisting of <strong>once-weekly</strong> doses of <strong>Isoniazid</strong> (H) and <strong>Rifapentine</strong> (P) for <strong>12 weeks.</strong></li>\n<li>6H: A regimen consisting of daily Isoniazid for 6 months.</li>\n<li>9H: A regimen consisting of daily Isoniazid for 9 months.</li>\n</ul>\n<p>TPT is particularly important for individuals with latent TB who have a higher risk of developing active TB, such as those with HIV, close contacts of TB patients, or those with certain medical conditions that weaken the immune system.</p>\n<p>Other options: </p>\n<p>Option B: Research has demonstrated that the 3HP regimen offers better compliance and similar <strong>effectiveness</strong> compared to the traditional 6H and 9H regimens. The shorter duration of 3HP (once weekly for 12 weeks) makes it more convenient and tolerable for patients, which leads to higher adherence rates. Thus, there is a significant difference in patient compliance between these regimens, with 3HP showing clear advantages.</p>\n<p>Option C: Although <strong>3HP</strong> is generally considered <strong>safe,</strong> data suggests that the risk profile for adverse effects, including <strong>potential reproductive</strong> impacts like abortion, differs between regimens. Specifically, 6H may have a different side effect profile due to the <strong>prolonged exposure</strong> to the drug over six months, compared to the shorter and intermittent dosing of 3HP. </p>\n<p>Option D: Studies have confirmed that the 3HP regimen is <strong>as effective</strong> as 6H and 9H in preventing active tuberculosis (TB). Both regimens aim to prevent <strong>latent TB</strong> from <strong>progressing</strong> to <strong>active disease,</strong> and <strong>3HP</strong> has been shown to achieve similar outcomes with fewer doses, enhancing patient compliance.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6985",
      "difficulty": "medium"
    },
    {
      "text": "A female suffered a head injury from a road traffic accident. On examination, there is elevated intracranial pressure. Which diuretic among the following can be used in her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Mannitol"
        },
        {
          "id": 2,
          "text": "Hydrochlorothiazide"
        },
        {
          "id": 3,
          "text": "Spironolactone"
        },
        {
          "id": 4,
          "text": "Acetazolamide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In this patient with <strong>raised intracranial pressure</strong> after a <strong>road traffic accident, mannitol</strong> is the <strong>diuretic</strong> of <strong>choice</strong> in her management to reduce intracranial pressure. </p>\n<p>Mannitol is an osmotic diuretic that draws <strong>fluid</strong> out of the <strong>brain tissue</strong> and into the <strong>bloodstream</strong> as it forms a <strong>hypertonic</strong> solution when it reaches the bloodstream, thereby reducing intracranial pressure (ICP). It is commonly used in cases of <strong>traumatic brain injury</strong> or other conditions that cause <strong>elevated ICP.</strong> This effect helps to <strong>relieve pressure</strong> on the <strong>brain,</strong> preventing <strong>further damage.</strong></p>\n<p>Other options: </p>\n<p>The other diuretics listed Hydrochlorothiazide, Spironolactone, and Acetazolamide are not typically used for managing elevated ICP. They are not hypertonic solutes and thus do not lead to a rapid reduction of the ICP as mannitol does. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6983",
      "difficulty": "easy"
    },
    {
      "text": "A 2-year-old child presents to the emergency department with lethargy, difficulty feeding, and dehydration. His vitals are stable and his ECG is shown below. What is the next step in his management?",
      "choices": [
        {
          "id": 1,
          "text": "Synchronized cardioversion with 2J of current "
        },
        {
          "id": 2,
          "text": "Adenosine 0.1 mg/kg"
        },
        {
          "id": 3,
          "text": "Adenosine 0.2 mg/kg"
        },
        {
          "id": 4,
          "text": "Synchronized cardioversion with 1J of current"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This clinical history along the EKG showing <strong>narrow QRS complexes</strong> without <strong>P waves</strong> and <strong>pseudo R waves</strong> in aVR lead suggests paroxysmal supraventricular tachycardia (PSVT) and the next step in his management would be an initial dose of <strong>adenosine at 0.1 mg/kg</strong>.</p>\n<p>PSVT is a regular, narrow QRS complex tachycardia, most often caused due to an <strong>atrioventricular nodal re-entrant circuit</strong>. Patients may present with sudden onset <strong>palpitations</strong>, <strong>dizziness</strong>, and <strong>diaphoresis</strong>. </p>\n<p>Management involves slowing AV node conduction and <strong>vagal maneuvers</strong> (e.g., Valsalva maneuver, splashing cold water on the face) are the first step. If this does not work, <strong>intravenous (IV) adenosine</strong> is the drug of choice used to terminate the majority of PSVT episodes.</p>\n<p><strong>Adenosine</strong> is a very <strong>short-acting</strong> endogenous <strong>purine signal</strong> molecule. It is administered as a <strong>6 mg IV bolus</strong> over 2-3 seconds <strong>followed by a rapid flush</strong> with 20 mL NS. It can be followed up with a <strong>12 mg IV bolus</strong> dose if required. It causes <strong>membrane hyperpolarization</strong> of cardiac muscle cells to terminate the re-entrant circuit through the AV node.</p>\n<p>Since the <strong>action</strong> of the drug <strong>lasts for less than a minute</strong>, adverse effects are <strong>short-lived</strong>. These include transient <strong>shortness of breath</strong>, <strong>chest pain</strong>, <strong>hypotension</strong>, and <strong>cutaneous flushing</strong> due to vasodilation. It can however <strong>precipitate bronchospasm in asthmatics</strong> and verapamil is preferred in such patients.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d3d48754732b440fb17b875d2b52a8dax510x812.PNG\" alt=\"Explanation Image\"><p>When the patient is <strong>hemodynamically unstable</strong>, i.e., <strong>hypotension</strong> with unconsciousness or <strong>respiratory distress</strong>, <strong>QRS-synchronous direct current cardioversion</strong> is done.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2d4980e7ca344abdb4c864c7546e97d0x1280x1845.JPEG\" alt=\"Explanation Image\"><p>The given ECG shows <strong>pseudo R' waves</strong>:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/61107bbff6054604a20f8b083695fb2dx1279x685.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Anti-arrhythmic drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7d6c4d5ed4a54f70b2030d71f3d06969x1280x1697.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Class of antiarrhythmic drugs&nbsp;</strong></span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span><strong>Mechanism of action</strong></span></p>\n</td>\n<td>\n<p><span><strong>Effect on action potential duration</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class I</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IA</strong></span></p>\n<p><span>Procainamide</span></p>\n<p><span>Quinidine</span></p>\n<p><span>Disopyramide</span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span>Na+ channel blockers with significant K<sup>+</sup> channel blocking property</span></p>\n<p><span>&nbsp;</span></p>\n</td>\n<td>\n<p><span>Prolonged</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IB</strong></span></p>\n<p><span>Lidocaine</span></p>\n<p><span>Mexiletine</span></p>\n</td>\n<td><span>Na+ channel blockers with K<sup>+</sup> channel opening property&nbsp;</span></td>\n<td>\n<p><span>Shortened or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IC</strong></span></p>\n<p><span>Flecainide</span></p>\n<p><span>Propafenone</span></p>\n<p><span>Moricizine</span></p>\n</td>\n<td><span>Na+ channel blockers with negligible K<sup>+</sup> channel blocking property&nbsp;</span></td>\n<td>\n<p><span>Variable or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class II</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Propranolol</span></p>\n<p><span>Esmolol</span></p>\n</td>\n<td><span>&beta;- blockers</span></td>\n<td><span>-&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class III</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Amiodarone, dronedarone</span></p>\n<p><span>Dofetilide</span></p>\n<p><span>Sotalol</span></p>\n<p><span>Ibutilide</span></p>\n<p><span>Vernakalant</span></p>\n</td>\n<td><span>K<sup>+</sup> channel blockers&nbsp;</span></td>\n<td><span>Prolonged&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IV</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Verapamil</span></p>\n<p><span>Diltiazem</span></p>\n</td>\n<td><span>Ca<sup>2+</sup> channel blockers</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Miscellaneous</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Adenosine</span></p>\n</td>\n<td><span>Activates adenosine receptors</span></td>\n<td><span>Shortened</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Digoxin</span></p>\n</td>\n<td><span>Na<sup>+</sup>-K<sup>+</sup> ATPase inhibitor</span></td>\n<td><span>Increases AV node refractoriness</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Magnesium</span></p>\n</td>\n<td><span>Unknown</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f29f9fa43ba346a29a54c1f5a649c32c.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6958",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs when added with erythromycin can lead to torsades de pointes?",
      "choices": [
        {
          "id": 1,
          "text": "Doxylamine"
        },
        {
          "id": 2,
          "text": "Loratidine"
        },
        {
          "id": 3,
          "text": "Promethazine"
        },
        {
          "id": 4,
          "text": "Astemizole"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Among the given drugs, <strong>astemizole</strong> increases the risk of Torsades de pointes when used concomitantly with erythromycin. </p>\n<p>Drugs that <strong>block potassium channels</strong> and prolong <strong>QT increase arrhythmogenic</strong> potential. Astemizole is a <strong>second-generation antihistamine</strong> that <strong>blocks</strong> delayed potassium channels and prolongs the QT interval.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Doxylamine</strong> is an <strong>antihistamine</strong> commonly used as a <strong>short-term treatment</strong> for <strong>insomnia.</strong> It is combined with pyridoxine (vitamin B6) to treat nausea and vomiting during pregnancy (morning sickness). It does <strong>not</strong> prolong the QT interval.</p>\n<p><span>Option B: <strong>Loratadine</strong> is a <strong>second-generation</strong> antihistamine used to treat allergic rhinitis (hay fever) and urticaria (hives). It is known for being non-sedating due to its minimal penetration into the central nervous system. It does <strong>not</strong> prolong the QT interval.</span></p>\n<p>Option C: <strong>Promethazine</strong> is a <strong>first-generation</strong> antihistamine with multiple uses, including the treatment of allergies, motion sickness, nausea and vomiting, and as a sedative or sleep aid. It also has antiemetic properties and is sometimes used in the management of <strong>postoperative nausea</strong> and <strong>vomiting.</strong></p><hr><h3>Related Pearl: Etiology of Torsade De Pointes</h3><p><strong>Acquired prolongation of QT interval</strong></p>\n<p><strong>Electrolyte abnormalities</strong></p>\n<ul>\n<li>Hypokalemia</li>\n<li>Hypomagnesemia</li>\n<li>Hypocalcemia</li>\n</ul>\n<p><strong>Drugs</strong></p>\n<ul>\n<li><strong>Antiarrhythmic drugs</strong>\n<ul>\n<li>Class IA: Quinidine, disopyramide, procainamide</li>\n<li>Class III: Sotalol, amiodarone (QT prolongation common but torsade ventricular tachycardia is rare), ibutilide, dofetilide, almokalant</li>\n</ul>\n</li>\n<li><strong>Antibiotics</strong>\n<ul>\n<li>Macrolides: Erythromycin, clarithromycin, azithromycin</li>\n<li>Fluoroquinolones: Levofloxacin, moxifloxacin, gatifloxacin</li>\n<li>Trimethoprim-sulfamethoxazole</li>\n<li>Clindamycin</li>\n<li>Pentamidine</li>\n<li>Chloroquine</li>\n<li>Antifungals: Ketoconazole, itraconazole</li>\n<li>Antivirals</li>\n<li>Antipsychotics</li>\n<li>Antihistamines</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6957",
      "difficulty": "medium"
    },
    {
      "text": "A child was started on ciclesonide inhalational therapy for bronchial asthma. Which of the following statements is incorrect regarding his treatment?",
      "choices": [
        {
          "id": 1,
          "text": "It has fewer side effects compared to other inhalational steroids "
        },
        {
          "id": 2,
          "text": "It is a prodrug metabolised by bronchial esterase"
        },
        {
          "id": 3,
          "text": "The occurence of oral candidiasis is more compared to other inhaled steroids"
        },
        {
          "id": 4,
          "text": "Oral bioavailability is negligible "
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The incorrect statement is option C as <strong>ciclesonide</strong> has a <strong>lower risk</strong> of <strong>oral candidiasis</strong> as compared to <strong>other inhaled steroids</strong>.</p>\n<p><strong>Ciclesonide</strong> is an <strong>inhaled corticosteroid</strong> that is unique because it is a <strong>prodrug.</strong> It is metabolised by <strong>bronchial esterases</strong> in the <strong>lungs</strong> to its active form, which allows for <strong>targeted action</strong> within the <strong>airways.</strong> This feature <strong>reduces</strong> <strong>systemic side effects</strong> and the risk of <strong>local side effects,</strong> such as <strong>oral candidiasis</strong> (thrush), compared to other inhaled steroids.</p>\n<p>Other options:</p>\n<p>Option A: Ciclesonide's activation in the lungs minimises systemic absorption, leading to fewer side effects.</p>\n<p>Option B: Ciclesonide is inactive until it is converted to its active form in the lungs.</p>\n<p>Option D: Due to its prodrug nature and metabolism in the lungs, ciclesonide has low oral bioavailability, reducing systemic exposure.</p><hr><h3>Related Pearl: Treatment of Asthma based on severity of symptoms (GINA-2022)</h3><p>Asthma management - GINA 2022</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3349e17dd3a64530b8cda3c9732af613x1280x3702.792665726375.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6956",
      "difficulty": "easy"
    },
    {
      "text": "A patient diagnosed with hypertriglyceridemia was started on a medication, following which, he developed flushing, hyperglycemia, and elevated liver enzymes. Identify the drug consumed by the patient.",
      "choices": [
        {
          "id": 1,
          "text": "Nicotinamide"
        },
        {
          "id": 2,
          "text": "Rosuvastatin"
        },
        {
          "id": 3,
          "text": "Ezetemibe"
        },
        {
          "id": 4,
          "text": "Fenofibrate"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The drug most likely responsible for causing <strong>flushing, hyperglycemia,</strong> and elevated liver enzymes in a patient being treated for <strong>hypertriglyceridemia</strong> is <strong>Nicotinamide</strong> (Niacin). </p>\n<p>Niacin (nicotinic acid), is commonly used to treat hypertriglyceridemia and hypercholesterolemia. However, it is associated with side effects such as <strong>flushing,</strong> which is due to <strong>prostaglandin-mediated vasodilation.</strong> Niacin can also lead to <strong>hyperglycemia</strong> by <strong>impairing insulin sensitivity</strong> and may cause <strong>elevated liver enzymes,</strong> indicating <strong>potential hepatotoxicity.</strong> </p>\n<p>Other options: </p>\n<p>Option B: <strong>Rosuvastatin</strong> is a statin, primarily used to lower <strong>LDL</strong> cholesterol, and while it may elevate liver enzymes, it is less commonly associated with flushing and hyperglycemia. It can cause <strong>myopathy</strong> in patients. </p>\n<p>Option C: <strong>Ezetimibe</strong> inhibits <strong>cholesterol absorption</strong> in the intestines and is not typically associated with these side effects.</p>\n<p>Option D: <strong>Fenofibrate</strong> is used to lower <strong>triglycerides</strong> can elevate <strong>liver enzymes</strong> and can increase the risk of developing myopathy if used concomitantly with statins, but it does not commonly cause flushing or hyperglycemia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6955",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following reasons best explains the combination of Atropine (0.025 mg) and Diphenoxylate (2.5 mg) for treating secretory diarrhoea?",
      "choices": [
        {
          "id": 1,
          "text": "Atropine potentiates the action of smooth muscle relaxation"
        },
        {
          "id": 2,
          "text": "It prevents overdose and abuse of Diphenoxylate"
        },
        {
          "id": 3,
          "text": "It antagonizes the side effect of Diphenoxylate"
        },
        {
          "id": 4,
          "text": "Atropine increases the antimotility action of diphenoxylate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Atropine</strong> is included in combination with <strong>diphenoxylate</strong> to prevent <strong>abuse</strong> and <strong>overdose</strong> of diphenoxylate. </p>\n<p><strong>Diphenoxylate</strong> is structurally similar to <strong>opioids</strong> and has the <strong>potential</strong> for <strong>misuse</strong> at <strong>higher doses.</strong> Additionally, it crosses the <strong>blood-brain</strong> barrier, making it more likely to cause dependence. The anticholinergic effects of atropine (e.g., dry mouth, tachycardia, blurred vision) become prominent at <strong>higher doses,</strong> discouraging overdose.</p>\n<p><strong>Diphenoxylate</strong> is an opioid agonist primarily used as an <strong>antidiarrheal</strong> agent. It works by slowing down <strong>intestinal motility,</strong> allowing more time for water and <strong>electrolytes</strong> to be absorbed from the intestines, which helps <strong>reduce diarrhea.</strong> However, because of its structural similarity to opioids, diphenoxylate has the potential for abuse and dependence if taken in large doses.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6954",
      "difficulty": "medium"
    },
    {
      "text": "A hypertensive patient is started on a drug to control his BP. He had complaints of dry mouth, drowsiness, and confusion after taking this drug, but he still continued to take the drug for 1 year. He had to travel abroad for work, and he forgot to take his medications. He now presents with a blood pressure of 200/120mmHg. Identify the drug he was on?",
      "choices": [
        {
          "id": 1,
          "text": "Amlodipine"
        },
        {
          "id": 2,
          "text": "Atenolol"
        },
        {
          "id": 3,
          "text": "Clonidine"
        },
        {
          "id": 4,
          "text": "Enalapril"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> adverse effects</strong> seen in this patient and the presentation of <strong>rebound hypertension</strong> on <strong>sudden drug withdrawal</strong> indicate that the drug is <strong>clonidine</strong>. </p>\n<p>Clonidine is an <strong>alpha-2 receptor agonist</strong> and a centrally-acting <strong>antihypertensive</strong> agent. It treats high blood pressure by stimulating <strong>presynaptic α<sub>2</sub> receptors</strong> in the vasomotor center in the brainstem. This binding has a <strong>sympatholytic</strong> <strong>effect</strong>, by <strong>suppressing </strong>the release of <strong>norepinephrine</strong> and other sympathomimetics.</p>\n<p>Abrupt withdrawal after long-term therapy can result in <strong>rebound hypertension, </strong>restlessness, and sympathetic overactivity. <strong>Dry mouth</strong> and <strong>sedation</strong> are the major side effects of clonidine. It can also cause <strong>impotency</strong> and <strong>constipation. Rebound hypertension </strong>is a potentially serious complication and occurs<strong> </strong>if the drug is <strong>missed</strong> for<strong> 1–2 days</strong>. This is associated with an<strong> alarming rise </strong>in <strong>blood pressure </strong>which may be <strong>more</strong> than the<strong> pretreatment level.</strong></p>\n<div class=\"page\" title=\"Page 171\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Phentolamine</strong> is used for the control of hypertension due to clonidine withdrawal.</p>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6953",
      "difficulty": "easy"
    },
    {
      "text": "In which phase of clinical trials is drug dosing done?",
      "choices": [
        {
          "id": 1,
          "text": "Phase I"
        },
        {
          "id": 2,
          "text": "Phase II"
        },
        {
          "id": 3,
          "text": "Phase III"
        },
        {
          "id": 4,
          "text": "Phase IV"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>dosing</strong> of a new drug is tested in <strong>phase I </strong>of a clinical trial.</p>\n<p>Phase I trials are usually performed on<strong> healthy volunteers </strong>to check the<strong> safety </strong>and <strong>pharmacokinetic properties </strong>of a drug. The participants in this phase do not gain any direct health benefits from taking part. They are generally <strong>paid a fee </strong>for their time, with the payments being regulated and not related to the risk involved.</p>\n<p>In clinical trials, <strong>drug dosing</strong> typically occurs in Phase I, where researchers establish the <strong>optimal dose</strong> to achieve desired effects while <strong>minimizing side effects</strong>. In these phases, they focus on s<strong>afety, tolerability,</strong> and <strong>pharmacokinetics</strong>.</p>\n<p><strong>Dose-ranging</strong>, primarily conducted in <strong>Phase II trials</strong>, involves <strong>testing multiple doses</strong> to identify the <strong>most effective</strong> and <strong>safe dose range</strong>. This phase helps determine the <strong>minimum effective dose</strong> and<strong> maximum tolerated dose</strong>, providing critical data for subsequent studies in Phase 3, where the chosen dose is tested for efficacy and safety in a larger population.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6952",
      "difficulty": "hard"
    },
    {
      "text": "A patient with a gynecological malignancy is started on Methotrexate. Later she develops oral and gastric ulcers. Which nucleotide synthesis is affected in her?",
      "choices": [
        {
          "id": 1,
          "text": "UDP"
        },
        {
          "id": 2,
          "text": "CTP"
        },
        {
          "id": 3,
          "text": "TMP"
        },
        {
          "id": 4,
          "text": "GMP"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>TMP synthesis </strong>is <strong>affected </strong>due to<strong> methotrexate. </strong></p>\n<p><strong>Methotrexate</strong> inhibits <strong>dihydrofolate reductase</strong> (DHFR), which is required to <strong>synthesize tetrahydrofolate. Tetrahydrofolate</strong> is essential for converting <strong>dUMP</strong> to <strong>dTMP</strong> (thymidine monophosphate) in the <strong>nucleotide synthesis</strong> pathway. Therefore, the <strong>nucleotide synthesis</strong> affected in this patient is <strong>TMP (thymidine monophosphate).</strong></p>\n<p>By inhibiting DHFR, methotrexate <strong>reduces</strong> the <strong>availability</strong> of <strong>THF,</strong> thereby disrupting the production of <strong>thymidylate</strong> (TMP), which is necessary for <strong>DNA replication</strong> and <strong>repair.</strong> This disruption leads to <strong>impaired DNA synthesis</strong> in rapidly dividing cells, such as cancer cells. However, it also affects other rapidly dividing cells, including those in the <strong>gastrointestinal</strong> tract and <strong>oral mucosa,</strong> leading to <strong>side effects</strong> like <strong>oral</strong> and <strong>gastric ulcers.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d865b671317e4be1a17a74242c10f2d4x1280x1905.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Uses of methotrexate (mnemonic: CANCER)</h3><p>Mnemonic: <strong>CANCER</strong></p>\n<p><strong>C</strong>rohn&rsquo;s disease</p>\n<p><strong>A</strong>bortion</p>\n<p><strong>N</strong>on-Hodgkin lymphoma, ALL</p>\n<p><strong>C</strong>horiocarcinoma, Sarcoma</p>\n<p><strong>E</strong>ctopic pregnancy</p>\n<p><strong>R</strong>heumatoid arthritis, Psoriasis, Vasculitis</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6951",
      "difficulty": "medium"
    },
    {
      "text": "The drug 'X' is a GHRH analogue that is FDA-approved for the treatment of HIV-associated lipodystrophy and not used for Growth hormone deficiency. Identify the drug 'X'.<div class='question-desc-html'><p>GHRH- Growth Hormone Releasing Hormone</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Octreotide"
        },
        {
          "id": 2,
          "text": "Somatropin"
        },
        {
          "id": 3,
          "text": "Tesamorelin"
        },
        {
          "id": 4,
          "text": "Mecasermin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Tesamorelin</strong> is approved for use in <strong>HIV-associated lipodystrophy</strong> but <strong>not</strong> for <strong>GH deficiency</strong>. It is a<strong> synthetic N-terminal modified </strong>form of human GHRH<strong>.</strong> It does not get degraded by dipeptidyl peptidase 4 and therefore has a longer duration of action.</p>\n<p>It increases the levels of growth hormone (GH) and insulin-like growth factor (IGF-1) but reduces visceral fat accumulation.</p>\n<p>Tesamorelin is approved for use in HIV-associated lipodystrophy but <strong>not</strong> for <strong>GH</strong> <strong>deficiency.</strong> </p>\n<p>Other options:</p>\n<p>Option A: <strong>Octreotide </strong>is a <strong>somatostatin analogue</strong> that decreases growth hormone levels. It is used in the treatment of <strong>acromegaly</strong>, <strong>variceal bleeding,</strong> diarrhoea due to adenomas secreting VIP (vasoactive intestinal peptide), and <strong>sulfonylurea toxicity.</strong> One of its adverse effects is <strong>gallstone</strong> formation.</p>\n<p>Option B: <strong>Somatropin </strong>is a <strong>growth hormone analogue</strong>. It is used in growth hormone deficiency and other short-stature conditions like Turner's syndrome, Noonan syndrome, and Prader-Willi syndrome. Their use is contraindicated in acute critical illness, active malignancy, and proliferative retinopathy.</p>\n<p>Option D: <strong>Mecasermin </strong>is a <strong>recombinant human IGF-1</strong>. It is used in IGF-1 deficiency, growth hormone receptor defects, and antibodies against growth hormone receptors. Adverse effects include <strong>hypoglycemia</strong> and <strong>lipohypertrophy</strong>. Another recombinant human IGF-1 with its IGFBP-3, <strong>mecasermin rinfabate</strong> has been FDA-approved for <strong>HIV-associated adipose redistribution syndrome</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1817",
      "difficulty": "medium"
    }
  ]
}